Drug intelligence / Profile preview

DST-201

Development stage: Preclinical
Lead developer: DelSiTech
Modality: Small Molecules
Administration: Subcutaneous, Implant

Overview

DST-201 is a preclinical-stage, long-acting small molecule therapeutic being developed by DelSiTech for the management of pain. The drug utilizes DelSiTech's proprietary Silica Matrix technology, which allows for the controlled, sustained release of the active pharmaceutical ingredient over an extended period. This technology is based on a biodegradable silica paste or implant that dissolves slowly in the body, potentially reducing the frequency of administration and improving patient compliance in chronic or acute pain settings.

Beyond the preview

Go deeper on DST-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DST-201.

Explore the full profile